Antagonizing interleukin-5 receptor ameliorates dextran sulfate sodium-induced experimental colitis in mice through reducing NLRP3 inflammasome activation
European Journal of Pharmacology · 2024
DOI: 10.1016/j.ejphar.2024.176331 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Yitao Ou und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and …. Hauptthemen laut MEDLINE: Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Guilin Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a condition characterized by inflammation in the gastrointestinal tract. Reducing intestinal inflammation is a promising approach for treating IBD. The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, a critical component of the innate immune system, is implicated in the pathogenesis of IBD. Therefore, inhibiting NLRP3 inflammasome activation is a potential therapeutic strategy for IBD. In this study, we investigated the effects of the interleukin-5 (IL-5) receptor antagonist YM-90709 on dextran sulfate sodium-induced experimental colitis in mice. We found that YM-90709 reduced the expressions of IL-1β and caspase-1 p20 in the colon and ameliorated colitis. Furthermore, we identified YM-90709 as an effective agent for inhibiting NLRP3 inflammasome activation. Knockdown of IL-5 receptor or using an inhibitor of STAT5, a key transcription factor downstream of the IL-5/IL-5 receptor signal pathway, also reduced NLRP3 inflammasome-dependent IL-1β release and ASC speck formation. Our study is the first to demonstrate that the NLRP3 inflammasome may be a downstream signal of IL-5/IL-5 receptor and that YM-90709 protects against IBD by inhibiting IL-5 receptor. These findings suggest a new strategy for regulating intestinal inflammation and managing IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical…
Förderung
- Guilin Medical University
- National Natural Science Foundation of China
Zitieren
APA
Ou, Y., Yang, Z., Zhou, Y., Yue, H., Hua, L., Liu, Z., Lin, G., Cai, H., Chen, Y., Hu, W., & Sun, P. (2024). Antagonizing interleukin-5 receptor ameliorates dextran sulfate sodium-induced experimental colitis in mice through reducing NLRP3 inflammasome activation. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176331
Vancouver
Ou Y, Yang Z, Zhou Y, Yue H, Hua L, Liu Z, et al. Antagonizing interleukin-5 receptor ameliorates dextran sulfate sodium-induced experimental colitis in mice through reducing NLRP3 inflammasome activation. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176331
BibTeX
@article{Ou2024,
author = {Ou, Yitao and Yang, Zhongjin and Zhou, Yinghua and Yue, Hu and Hua, Lei and Liu, Zhuorong and Lin, Geng and Cai, Haowei and Chen, Yanhong and Hu, Wenhui and Sun, Ping},
title = {Antagonizing interleukin-5 receptor ameliorates dextran sulfate sodium-induced experimental colitis in mice through reducing NLRP3 inflammasome activation},
journal = {European Journal of Pharmacology},
year = {2024},
doi = {10.1016/j.ejphar.2024.176331}
}
EUVIMED